News | March 18, 2026
Sun Pharma scores FDA review for ILUMYA in psoriatic arthritis
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
The designation for HCB101covers all forms of gastric cancer, including advanced gastric adenocarcinoma in both HER2-positive and HER2-negative patients
If approved, Ameluz would become the first and only photodynamic therapy (PDT) photosensitizer for sBCC in the US
The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses
Under the agreement, Apotex’s branded division, Searchlight Pharma, will seek regulatory approval and handle marketing and distribution in Canada
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The trial also revealed statistically significant and clinically meaningful gains in key patient-reported outcomes
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
Subscribe To Our Newsletter & Stay Updated
